Skip to main content

Market Overview

Biogen, Capsigen Ink $1.3B AAV Capsids Development Pact For CNS & Neuromuscular Disorders

Share:
Biogen, Capsigen Ink $1.3B AAV Capsids Development Pact For CNS & Neuromuscular Disorders
  • Biogen Inc (NASDAQ: BIIB) and Capsigen Inc have entered into a strategic research collaboration to engineer novel adeno-associated virus (AAV) capsids with the potential to deliver gene therapies for various CNS and neuromuscular disorders.
  • As a part of the collaboration, Capsigen's proprietary TRADE platform and associated technologies will be utilized to create and identify novel AAV capsids.
  • Under the terms of the agreement, Biogen will receive an exclusive license under Capsigen's proprietary technology for an undisclosed number of CNS and neuromuscular disease targets.
  • Capsigen will receive a $15 million upfront payment and is eligible to receive up to $42 million in potential research milestones and up to an additional $1.25 billion in potential development and commercial payments.
  • Price Action: BIIB shares closed 0.6% higher at $275.61 on Monday.
 

Related Articles (BIIB)

View Comments and Join the Discussion!

Posted-In: Briefs Neuromuscular DisorderBiotech News Health Care Contracts General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com